Tools
Tools
Metcalfe, Christopher, Muzaffar, Jameel, Kulendra, Kevin, Sanghera, Paul, Shaw, Simon, Shad, Amjad, Saravanappa, Natarajan, Paluzzi, Alessandro and Ahmed, Shahzada (2021) Chordomas and chondrosarcomas of the skull base: treatment and outcome analysis in a consecutive case series of 24 patients. World journal of surgical oncology, 19 (1). p. 68. ISSN 1477-7819. This article is available to all UHB staff and students via ASK Discovery tool http://tinyurl.com/z795c8c by using their UHB Athens login IDs
|
Text (PDF file format)
12957_2021_Article_2178.pdf - Published Version Available under License Creative Commons Attribution 4.0. Download (274kB) | Preview |
Abstract
BACKGROUND
We present our 9-year consecutive case series of skull base chordomas and chondrosarcomas from a UK tertiary referral centre, discussing treatments offered and outcomes. This was carried out to improve understanding around current treatment and to better inform the management of future patients.
METHODS
Consecutive case series over a 9-year period (2007-2016). Retrospective data analysis from the electronic skull base multidisciplinary team database and the digital patient records at a UK tertiary referral centre RESULTS: Twenty-four patients were identified (11 chordomas, 13 chondrosarcomas, mean age 52). Nineteen had proton beam therapy (PBT) postoperatively; two had intensity-modulated radiotherapy; two had no further treatment. One patient was lost to follow-up. All chordomas were resected via a transnasal endoscopic approach. Of the 19 patients undergoing resection with PBT, 13 were disease free at latest follow-up, and six patients had local recurrence, of which two died (mean follow up 7.4 years). Of the three patients treated with surgery then IMRT/TomoTherapy, one died 4 years post-treatment, and the other two are alive after 4 and 5 years of follow-up respectively. Of the two patients treated with surgery alone, one was lost to follow-up, and the other is alive after more than 8 years. Chondrosarcoma 5-year survival was 91.6%, and chordoma 4-year survival was 75%.
CONCLUSION
Skull base chordomas and chondrosarcomas can be challenging to resect, and most cases require adjuvant therapy to achieve control. Where complete resection is not possible, it is critical to undertake sufficient resection to permit high-dose radiation.
| Item Type: | Article |
|---|---|
| Additional Information: | This article is available to all UHB staff and students via ASK Discovery tool http://tinyurl.com/z795c8c by using their UHB Athens login IDs |
| Subjects: | QA Mathematics. Computing QZ Pathology. Oncology W Public health. Health statistics. Occupational health. Health education |
| Divisions: | Planned IP Care > Oncology and Clinical Haematology |
| Related URLs: | |
| Depositing User: | Jamie Edgar |
| Date Deposited: | 31 Mar 2021 12:47 |
| Last Modified: | 31 Mar 2021 12:47 |
| URI: | http://www.repository.uhblibrary.co.uk/id/eprint/4156 |
Actions (login required)
 |
View Item |
